Who are DHA-paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colchicine Pill, Carboplatin+Paclitaxel, Carboplatin plus Paclitaxel, Cisplatin and Docetaxel, Bevacizumab and Paclitaxel, IVM plus ALB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dha-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DHA-paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DHA-paclitaxel (DHA-paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 2 Taxane Beta-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DHA-paclitaxel (DHA-paclitaxel) — Theradex. Paclitaxel binds to tubulin, inhibiting microtubule formation and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DHA-paclitaxel TARGET	DHA-paclitaxel	Theradex	phase 2	Taxane	Beta-tubulin
Colchicine Pill	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
Carboplatin+Paclitaxel	Carboplatin+Paclitaxel	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Carboplatin plus Paclitaxel	Carboplatin plus Paclitaxel	The University of Hong Kong	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Cisplatin and Docetaxel	Cisplatin and Docetaxel	Swiss Cancer Institute	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); beta-tubulin (docetaxel)
Bevacizumab and Paclitaxel	Bevacizumab and Paclitaxel	Central European Cooperative Oncology Group	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy	VEGF (bevacizumab); beta-tubulin (paclitaxel)
IVM plus ALB	IVM plus ALB	University Hospitals Cleveland Medical Center	phase 3	Antiparasitic combination	Glutamate-gated chloride channels (ivermectin); beta-tubulin (albendazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

Sanofi · 3 drugs in this class
Akeso · 1 drug in this class
Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Central European Society for Anticancer Drug Research · 1 drug in this class
Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Jina Pharmaceuticals Inc. · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DHA-paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/dha-paclitaxel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing